Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DME7KRM)

• Drug Name: Oxiconazole Drug Info
• Synonyms: Oxiconazol; Oxiconazolum; Oxyconazole; Oxiconazol [INN-Spanish]; Oxiconazole (INN); Oxiconazole [INN:BAN]; Oxiconazolum [INN-Latin]; Ro 13-8996; Sgd 301-76; RO-13-8996; (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-O-(2,4-dichlorobenzyl) ethanone oxime nitrate; 1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine; 2',4'-Dichlor-O-(2,4-dichlorbenzyl)-2-(1-imidazolyl)-(Z)-acetophenonoxim; 2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-(O-(2,4-dichlorobenzyl)oxime)
• Therapeutic Class: Antifungal Agents
• Cross-matching ID:
  PubChem CID: 5353853
  ChEBI ID: CHEMBL1262
  CAS Number: CAS 64211-45-6
  TTD Drug ID: D04GYO
  INTEDE Drug ID: DR1215

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Proteasome	2.27	0.00e+0	44/46 (95.65%)	PSMD11;PSMD14;PSMA7;...
DNA replication	2.18	0.00e+0	34/36 (94.44%)	PCNA;MCM5;RPA3;...
Spliceosome	2.01	0.00e+0	101/150 (67.33%)	HSPA8;LSM5;HSPA6;...
Mismatch repair	1.95	0.00e+0	22/23 (95.65%)	PCNA;RPA3;MSH2;...
Ribosome biogenesis in eukaryotes	1.91	3.49e-3	52/108 (48.15%)	NVL;NXT1;NOP56;...
Base excision repair	1.88	5.81e-3	29/33 (87.88%)	PCNA;APEX1;FEN1;...
Fat digestion and absorption	1.82	7.47e-3	35/43 (81.4%)	CD36;ACAT2;PLPP2;...
Pyrimidine metabolism	1.82	6.54e-3	40/56 (71.43%)	NME1;DCTPP1;ENPP1;...
RNA degradation	1.81	5.81e-3	53/79 (67.09%)	LSM5;TENT4A;PAN2;...
Homologous recombination	1.79	6.10e-3	35/41 (85.37%)	RPA3;RBBP8;RAD51C;...
Fanconi anemia pathway	1.71	3.17e-2	36/54 (66.67%)	RPA3;FANCG;CENPX;...
Vitamin digestion and absorption	1.68	3.71e-2	17/24 (70.83%)	SLC19A1;SCARB1;SLC19A2;...
Pancreatic cancer	-1.66	3.67e-2	75/76 (98.68%)	KRAS;CDK6;ARHGEF6;...
Tryptophan metabolism	-1.67	3.43e-2	35/42 (83.33%)	EHHADH;DHTKD1;ALDH8A1;...
Histidine metabolism	-1.67	3.37e-2	16/22 (72.73%)	ALDH2;ALDH3B1;AOC1;...
Viral protein interaction with cytokine and cytokine re...	-1.68	3.51e-2	84/100 (84%)	CCL22;IL2RB;CCR7;...
AGE-RAGE signaling pathway in diabetic complications	-1.75	1.72e-2	97/100 (97%)	COL4A3;MAPK13;PLCG1;...
NF-kappa B signaling pathway	-1.78	1.44e-2	90/104 (86.54%)	ATM;TRAF6;LCK;...
Chagas disease	-1.80	8.64e-3	93/102 (91.18%)	TNF;CFLAR;IL6;...
T cell receptor signaling pathway	-1.83	8.43e-3	93/104 (89.42%)	DLG1;MAPK13;NCK1;...
African trypanosomiasis	-1.85	8.17e-3	32/37 (86.49%)	TNF;IL6;IL12A;...
Amoebiasis	-1.86	6.74e-3	99/102 (97.06%)	GNAS;CASP3;LAMA4;...
Pertussis	-1.88	6.24e-3	64/76 (84.21%)	CASP3;RHOA;MAPK8;...
Natural killer cell mediated cytotoxicity	-1.91	5.62e-3	99/131 (75.57%)	ICAM2;TNFSF10;KIR2DL1;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.93	4.81e-3	62/70 (88.57%)	MAPK13;ATP6V0A4;PLCG1;...
Th17 cell differentiation	-1.96	3.74e-3	95/107 (88.79%)	MAPK13;HLA-DPB1;PLCG1;...
Rheumatoid arthritis	-1.99	2.25e-3	78/93 (83.87%)	ATP6V0A4;HLA-DPB1;TNFSF11;...
Graft-versus-host disease	-2.10	0.00e+0	32/42 (76.19%)	KIR2DL1;HLA-DPB1;CD80;...
Th1 and Th2 cell differentiation	-2.14	0.00e+0	80/92 (86.96%)	MAPK13;HLA-DPB1;PLCG1;...
TNF signaling pathway	-2.17	0.00e+0	103/112 (91.96%)	TNF;CFLAR;IL6;...
IL-17 signaling pathway	-2.28	0.00e+0	84/94 (89.36%)	CXCL10;MMP1;FADD;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	8uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼